EP2010513A2 - Novel crystalline compounds - Google Patents

Abstract

The invention relates to the novel crystalline compounds A of general formula (I), wherein A1, A2, A3, X, Y1, Y2, and Y3 are defined as indicated in claim 1, and which are provided in the form of the physiologically acceptable salts thereof with acids, said acids being selected among group B comprising hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, benzenesulfonic acid, p-toluenesulfonic acid, maleic acid, succinic acid, fumaric acid, D-(-)-tartaric acid, L-(+)-tartaric acid, naphthalene-2-sulfonic acid, and naphthalene-1,5-disulfonic acid, as well as the polymorphs, the respective solvates and hydrates.

Description

 NEW CRYSTALLINE COMPOUNDS

The present invention relates to the novel crystalline compounds A of the general formula I.

in which A ¹ , A ² , A ³ , X, Y ¹ , Y ² and Y ^{3 are} as defined in claim 1 and which are present in the form of their physiologically tolerable salts with acids, the acids being selected from group B. from hydrochloric, hydrobromic, sulfuric, phosphoric, benzenesulfonic, p-toluenesulfonic, maleic, succinic, fumaric, D - (-) - tartaric, L - (+) - tartaric, naphthalene-2-sulfonic and naphthalene-1, 5-disulfonic acid , as well as the polymorphs, the corresponding solvates and hydrates.

BACKGROUND OF THE INVENTION

TECHNICAL AREA

The present invention relates to CGRP antagonists, which are in the form of stable crystalline derivatives and are suitable for the treatment of headaches, in particular for the treatment of migraine.

STATE OF THE ART

International Patent Applications PCT / EP97 / 04862, PCT / EP03 / 11762, PCT / EP03 / 11763 and PCT / EP2005 / 003094 already describe CGRP antagonists, but not their crystalline forms. DETAILED DESCRIPTION OF THE INVENTION

The pharmacologically valuable properties of the compounds according to the invention represent the basic requirement for effective use of the compound as a medicament. However, an active ingredient must still meet other requirements in order to be used as a medicament. These parameters are largely related to the physicochemical nature of the drug.

Without limitation, examples of these parameters are the active stability of the starting material under various environmental conditions, stability in the course of preparation of the pharmaceutical formulation, and stability in the final compositions of the drug. The drug used to make the drug compositions should therefore have high stability, which must be ensured even under different environmental conditions. This is absolutely necessary in order to prevent the use of pharmaceutical compositions in which, in addition to the actual active substance, for example, degradation products thereof are contained. In such a case, an active ingredient content found in pharmaceutical formulations could be lower than specified.

The absorption of moisture reduces the content of drug due to the increase in weight caused by the absorption of water. Moisture-prone drugs must be protected from moisture during storage, for example by adding suitable drying agents or by storing the drug in a humidity protected environment. In addition, the ingestion of moisture may reduce the level of drug during manufacture if the drug is exposed to the environment without any protection from moisture. Preferably, therefore, a drug should only be slightly hygroscopic.

Since the crystal modification of an active substance is of importance for the reproducible active ingredient content of a dosage form, there is a need to elucidate possibly existing polymorphism of a crystalline active substance in the best possible way. If different polymorphic modifications of a drug occur, it should be ensured that the crystalline modification of the drug in the later drug preparation not changed. Otherwise, this could adversely affect the reproducible efficacy of the drug. Preference is given to this background active ingredients which are characterized only by low polymorphism.

Another criterion which, depending on the choice of formulation or the choice of the preparation process of the formulation of possibly outstanding importance, is the solubility of the active ingredient. If, for example, drug solutions (for example for infusions) are provided, adequate solubility of the active substance in physiologically compatible solvents is indispensable. Also for orally administered drugs sufficient solubility of the drug is of great importance.

It is an object of the present invention to provide a pharmaceutical active ingredient which is not only characterized by a high pharmacological activity, but also best meets the aforementioned physicochemical requirements.

It has surprisingly been found that the above object is achieved by the crystalline compounds according to the invention.

A first object of the present invention relates to the compounds of the above general formula I, in which

A ¹ Br, -CH ₃ , -CF ₃ or -C ₂ H ₅ ,

A ^{2 is} -NH ₂ , -OH or -C ₂ H ₅ ,

A ³ Br, Cl, -CH ₃ or H,

X is -CH ₂ -, -NH- or -O-,

Y ¹ N or CH,

Y ² N or CH and - A -

Y ^{3 is} -CH ₂ -, -N (CH ₃ ) - or -O-,

and which are present in the form of their physiologically tolerated salts with acids, the acids being selected from the group B consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, benzenesulphonic acid, p-toluenesulphonic acid, maleic acid, succinic acid, fumaric acid, D - (-) Tartaric acid, L - (+) - tartaric acid, naphthalene-2-sulfonic acid and naphthalene-1, 5-disulfonic acid, as well as the polymorphs, the corresponding solvates and hydrates.

A second aspect of the present invention relates to the novel crystalline CGRP antagonists A of general formula I which are selected from the group consisting of

and which are in the form of their physiologically acceptable salts with acids B selected from hydrochloric, hydrobromic, sulfuric, phosphoric, benzenesulphonic, p-toluenesulphonic, maleic, succinic, fumaric, D - (-) - tartaric, L - (+) Tartaric acid, naphthalene-2-sulfonic acid and naphthalene-1, 5-disulfonic acid, as well as the polymorphs, the corresponding solvates and hydrates.

Further objects of the present invention relate to the following compounds:

(1 a) 1 - [4-Amino-3,5-dibromo-Λ / - [[4- (2,3,4,5-tetrahydro-2 (1 H) -oxo-1,3-benzodiazepine] 3 -yl) -1-piperidinyl] carbonyl] -D-phenylalanyl] -4- (1-piperidinyl) -piperidine-p-toluenesulfonate, (1 b) 1 - [4-Amino-3,5-dibromo-Λ / - [[4- (2,3,4,5-tetrahydro-2 (1 H) -oxo-1,3-benzodiazepine] 3 -yl) -1-piperidinyl] carbonyl] -D-phenylalanyl] -4- (1-piperidinyl) -piperidine-benzenesulfonate,

(1c) 1 - [4-Amino-3,5-dibromo-Λ / - [[4- (2,3,4,5-tetrahydro-2 (1 H) -oxo-1,3-benzodiazepine] yl) -1-piperidinyl] carbonyl] -D-phenylalanyl] -4- (1-piperidinyl) -piperidine-maleate,

(2a) 4- (2-Oxo-1,2,4,5,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid (R) -

1- (4-amino-3-chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methyl-1-piperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl dimaleinate,

(2b) 4- (2-Oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid (R) -1- (4-amino-3-) chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidirid-1-yl] -2-oxo-ethyl ester hydrobromide,

(2c) 4- (2-Oxo-1,2,4,5,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid (R)-1- (4-amino-3-) chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidirid-1-yl] -2-oxo-ethyl ester dihydrobromide,

(2d) 4- (2-Oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid- (R) -1- (4-amino-3-) chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester hydrochloride,

(2e) 4- (2-Oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid- (R) -1- (4-amino-3-) chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidine

1-yl] -2-oxo-ethyl ester difumarate,

(2f) 4- (2-Oxo-1,2,4,5,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid (R) -

1- (4-amino-3-chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester disuccinate,

(2g) 4- (2-Oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid (R) -1- (4-amino-3-) chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester sulphate, (3a) 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / - 1, 3-benzdiazepin-3-yl) -

(1R) - 1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester hydrobromide

(3b) 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / - 1, 3-benzdiazepin-3-yl) -

(1R) - 1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester hydrochloride,

(3c) 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / - 1, 3-benzdiazepin-3-yl) -

(1R) - 1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester phosphate,

(3d) 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / - 1, 3-benzadiazepin-3-yl) - (1 R) -1 - [(4 -hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -

2-oxoethylester- (2R, 3R) -2,3-dihydroxybutanedioate,

(3e) 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / - 1, 3-benzdiazepin-3-yl) -

(1R) -1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester (2S, 3S) -2, 3-dihydroxybutanedioate,

(4a) 4- (2-Oxo-1, 2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - (I?) - 1 - (4-hydroxy-3 , 5-dimethyl-benzyl) -2-oxo-2- [4- (tetrahydropyran-4-yl) -piperazin-1-yl] -ethyl ester fumarate,

(4b) 4- (2-Oxo-1,2,4,5,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - (?) -1- (4-hydroxy-3 , 5-dimethyl-benzyl) -2-oxo-2- [4- (tetrahydropyran-4-yl) -piperazin-1-yl] -ethyl ester sulfate,

(5a) (S) -2- (4-Amino-3-chloro-5-trifluoromethyl-benzyl) -1 - [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -4 [4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidin-1-yl] -butane-1,4-dione hydrochloride pentahydrate, (5b) (S) -2- (4-Amino-3-chloro-5-trifluoromethyl-benzyl) -1 - [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -4 [4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidin-1-yl] -butane-1,4-dione (2S, 3S) -2,3-dihydroxybutanedioate,

(5c) (S) -2- (4-Amino-3-chloro-5-trifluoromethyl-benzyl) -1 - [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -4 [4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidin-1-yl] -butane-1,4-dione hydrobromide pentahydrate,

(6a) 4- (2-Oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid {(/?) - 1 - (3,4-) diethyl-benzyl) -2- [4- (1-methylpiperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl} -amide

Dimaleinat,

(6b) 4- (2-Oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid {(/?) - 1 - (3,4-) diethyl-benzyl) -2- [4- (1-methyl-piperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl} -amide-p-toluenesulfonate,

(6c) 4- (2-Oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - {(/?) - 1 - (3,4-) diethyl-benzyl) -2- [4- (1-methyl-piperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl} -amide-benzenesulfonate,

(6d) 4- (2-Oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - {(/?) - 1 - (3,4-) diethyl-benzyl) -2- [4- (1-methylpiperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl} -amide-naphthalene-1,5-disulfonate and

(6e) 4- (2-Oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - {(/?) - 1 - (3,4-) diethyl-benzyl) -2- [4- (1-methylpiperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl} -amide-naphthalene-2-sulfonate,

their polymorphs, their solvates and their hydrates.

The compounds of the invention are characterized by a high degree of stability and very readily soluble in physiologically acceptable solvents. The crystalline salts are each characterized by a characteristic melting point which was determined by means of differential scanning calorimetry (DSC: evaluation via onset temperature or peak maximum, heating rate: 10 ° C./min). The values of the individual compounds listed in Table 1 were determined by means of a DSC 821 from Mettler Toledo.

Table 1: Melting points of the crystalline salts according to the invention

Another preferred subject matter of the present invention therefore relates to the crystalline salts according to the invention, each characterized by their characteristic melting point.

Another preferred object relates to the crystalline compound (1a) characterized by a melting point of T _Smp = 180 ± 5 ° C.

Another preferred object relates to the crystalline compound (1 b), characterized by a melting point of T _Smp = 183 ± 5 ° C.

Another preferred object relates to the crystalline compound (1c) characterized by a melting point of T _Smp = 191 ± 5 ° C. Another preferred object relates to the crystalline compound (2a), characterized by a melting point of T _Smp = 200 ± 5 ° C.

Another preferred object relates to the crystalline compound (2b), characterized by a melting point of T _Smp = 238 ± 5 ° C.

Another preferred object relates to the crystalline compound (2c), characterized by a melting point of T _Smp = 277 ± 5 ° C.

Another preferred object relates to the crystalline compound (2e) characterized by a melting point of T _Sm p = 218 ± 5 ° C.

Another preferred object relates to the crystalline compound (2f) characterized by a melting point of T _Sm p = 133 ± 5 ° C.

Another preferred object relates to the crystalline compound (2g) characterized by a melting point of T _Sm p = 165 ± 5 ° C.

Another preferred object relates to the crystalline compound (3a), polymorph 1), characterized by a melting point of T _Smp = 186 ± 5 ° C.

Another preferred object relates to the crystalline compound (3a), polymorph 2), characterized by a melting point of T _Smp = 170 ± 5 ° C.

Another preferred object relates to the crystalline compound (3b), polymorph 1), characterized by a melting point of T _Sm p = 176 ± 5 ° C.

Another preferred object relates to the crystalline compound (3b), polymorph 2), characterized by a melting point of T _Smp = 174 ± 5 ° C.

Another preferred object relates to the crystalline compound (3c) characterized by a melting point of T _Sm p = 209 ± 5 ° C. Another preferred object relates to the crystalline compound (3d), characterized by a melting point of T _Smp = 195 ± 5 ° C.

Another preferred object relates to the crystalline compound (3d), characterized by a water content between 1.8 and 2.2%.

Another preferred object relates to the crystalline compound (3e) characterized by a melting point of T _Sm p = 175 ± 5 ° C.

Another preferred object relates to the crystalline compound (4a) characterized by a melting point of T _Sm p = 222 ± 5 ° C.

Another preferred object relates to the crystalline compound (4b) characterized by a melting point of T _Smp = 143 ± 5 ° C.

Another preferred subject matter relates to the crystalline compound (5a) characterized by a melting point of T _Smp = 136 ± 5 ° C.

Another preferred object relates to the crystalline compound (5b), characterized by a melting point of T _Smp = 144 ± 5 ° C.

Another preferred object relates to the crystalline compound (6a) characterized by a melting point of T _Sm p = 165 ± 5 ° C.

Another preferred object relates to the crystalline compound (6b) characterized by a melting point of T _Sm p = 142 ± 5 ° C.

Another preferred object relates to the crystalline compound (6c) characterized by a melting point of T _Sm p = 199 ± 5 ° C.

Another preferred object relates to the crystalline compound (6d) characterized by a melting point of T _Smp = 204 ± 5 ° C. Another preferred object relates to the crystalline compound (6e) characterized by a melting point of T _Smp = 172 ± 5 ° C.

The crystalline forms of the individual salts according to the invention were investigated in more detail by means of X-ray powder diffraction. The resulting diagrams are shown in FIGS. 1 to 25.

Tables 2 to 26 below summarize the data obtained from the analyzes performed.

Table 2: X-ray powder reflections and intensities (normalized) of the compound (1a)

Table 3: X-ray powder reflections and intensities (normalized) of the compound (1b)

Table 4: X-ray powder reflections and intensities (normalized) of compound (1c)

Table 5: X-ray powder reflections and intensities (normalized) of the compound (2a)

Table 6: X-ray powder reflections and intensities (normalized) of the compound (2b)

Table 7: X-ray powder reflections and intensities (normalized) of compound (2c)

Table 8: X-ray powder reflections and intensities (normalized) of compound (2d)

Table 9: X-ray powder reflections and intensities (normalized) of the compound (2e)

Table 10: X-ray powder reflections and intensities (normalized) of compound (2f)

Table 11: X-ray powder reflections and intensities (normalized) of compound (2g)

Table 12a: X-ray powder reflections and intensities (normalized) of the compound (3a) - polymorph 1

Table 12b: X-ray powder reflections and intensities (normalized) of compound (3a) polymorph 2

Table 13a: X-ray powder reflections and intensities (normalized) of the compound (3b) - polymorph 1

Table 13b: X-ray powder reflections and intensities (normalized) of compound (3b) - polymorph 2

Table 14: X-ray powder reflections and intensities (normalized) of compound (3c)

Table 15: X-ray powder reflections and intensities (normalized) of compound (3d)

Table 16: X-ray powder reflections and intensities (normalized) of compound (3e)

Table 17: X-ray powder reflections and intensities (normalized) of compound (4a)

Table 18: X-ray powder reflections and intensities (normalized) of compound (4b)

Table 19: X-ray powder reflections and intensities (normalized) of compound (5a)

Table 20: X-ray powder reflections and intensities (normalized) of compound (5b)

Table 21: X-ray powder reflections and intensities (normalized) of compound (5c)

Table 22: X-ray powder reflections and intensities (normalized) of compound (6a)

Table 23: X-ray powder reflections and intensities (normalized) of compound (6b)

Table 24: X-ray powder reflections and intensities (normalized) of compound (6c)

Table 25: X-ray powder reflections and intensities (normalized) of compound (6d)

Table 26: X-ray powder reflections and intensities (normalized) of compound (6e)

In the above Tables 2 to 26, the value "2 Θ [°]" stands for the diffraction angle in degrees and the value "d (hkl) [A]" for the determined distances in λ between the lattice planes.

The X-ray powder diagrams of the compounds (1a), (1 b), (1c), (5a), (5b), (5c), (6a), (6b), (6c), (6d) and (6e) have been described in U.S. Patent Nos. 4,199,431; Included within the scope of the present invention using a BRUKER D8-advanced system in bragg-brentano geometry, equipped with a position-sensitive detector (OED) and a Cu anode as X-ray source with filtered CuK _α radiation (λ = 1.5418 A, 40 kV, 40 mA).

The X-ray powder diagrams of compounds (2a), (2b), (2c), (2d), (2e), (2f), (2g), (3a), (3b), (3c), (3d), (3e ), (4a) and (4b) were recorded within the scope of the present invention by means of a STOE-STADI P diffractometer in the transmission mode, equipped with a position-sensitive detector (OED) and a Cu anode as X-ray source with monochromatic CuK _α radiation (λ = 1.54056 Ä, 40 kV, 40 mA).

According to the findings shown in Table 2, the present invention relates to crystalline 1 - [4-amino-3,5-dibromo-Λ / - [[4- (2,3,4,5-tetrahydro-2 (1 H) -oxo -1, 3-benzodiazepin-3-yl) -1-piperidinyl] carbonyl] -D-phenylalanyl] 4- (1-piperidinyl) -piperidine-p-toluenesulfonate (1a), characterized in that it is described in the X-ray powder diagram, inter alia, the characteristic values d = 19.49 Ä, 12.16 Ä, 6.46 Ä, 6.08 Ä, 5.4 Ä, 5.17 Ä and 3.82 Ä.

According to the findings shown in Table 3, the present invention relates to crystalline 1 - [4-amino-3,5-dibromo-Λ / - [[4- (2,3,4,5-tetrahydro-2 (1 H) -oxo -1, 3-benzodiazepin-3-yl) -1-piperidinyl] carbonyl] -D-phenylalanyl] 4- (1-piperidinyl) -piperidine-benzenesulfonate (1 b), characterized in that, in the X-ray powder diagram, it has, among others, the characteristic Values d = 17.6 Ä, 12.29 Ä, 7.24 Ä, 5.84 Ä and 5.34 Ä.

According to the findings shown in Table 4, the present invention relates to crystalline 1 - [4-amino-3,5-dibromo-Λ / - [[4- (2,3,4,5-tetrahydro-2 (1 H) -oxo -1,3-benzodiazepin-3-yl) -1-piperidinyl] carbonyl] -D-phenylalanyl] 4- (1-piperidinyl) -piperidine-maleinate (1c), characterized in that, in the X-ray powder diagram, it has, among others, the characteristic Values d = 16.14 Ä, 11.7 Ä, 6.3 Ä, 5.04 Ä, 4.61 Ä, 4.43 Ä, 4.03 Ä and 3.8 Ä.

According to the findings shown in Table 5, the present invention relates to crystalline 4- (2-oxo-1, 2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid (R) - 1- (4-Amino-3-chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl-ester-dimaleinate ( 2a), characterized in that it is in X-ray Among other things, the powder diagram has the characteristic values d = 7.92 Å, 5.45 Å, 5.29 Å, 4.99 Å, 4.66 Å, and 4.45 Å.

According to the findings shown in Table 6, the present invention relates to crystalline 4- (2-oxo-1, 2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid (R) - 1- (4-Amino-3-chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester hydrobromide ( 2b), characterized in that it has in the X-ray powder diagram, among others, the characteristic values d = 4.71 Ä, 4.49 Ä, 4.39 Ä, 3.77 Ä, 3.71 Ä and 3.45 Å.

According to the findings shown in Table 7, the present invention relates to crystalline 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid (R) - 1- (4-Amino-3-chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester dihydrobromide ( 2c), characterized in that it has in the X-ray powder diagram among others the characteristic values d = 21.69 Å, 5.81 Å, 4.74 Å, 4.63 Å, 4.15 Å and 3.78 Å.

According to the findings shown in Table 8, the present invention relates to crystalline 4- (2-oxo-1, 2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid (f?). -1- (4-amino-3-chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester hydrochloride (2d), characterized in that it has in the X-ray powder diagram, among others, the characteristic values d = 7.59 Ä, 5.78 Ä, 4.95 Ä, 4.69 Ä, 4.59 Ä, 4.12 Ä and 3.73 Ä.

According to the findings shown in Table 9, the present invention relates to crystalline 4- (2-oxo-1, 2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid (R) - 1- (4-Amino-3-chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester difumarate ( 2e), characterized in that it has in the X-ray powder diagram among others the characteristic values d = 8.16 Ä, 6.29 Ä, 5.21 Ä, 4.63 Ä, 4.37 Ä and 3.72 Ä.

According to the findings shown in Table 10, the present invention relates to crystalline 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid (R) - 1- (4-amino-3-chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methyl-piperazin-1-yl) -piperidine 1-yl] -2-oxo-ethyl ester disuccinate (2f), characterized in that in the X-ray powder diagram it has among others the characteristic values d = 8.18 Å, 6.46 Å, 5.26 Å, 5.18 Å, 4.61 Å and 4.32 Å ,

According to the findings shown in Table 11, the present invention relates to crystalline 4- (2-oxo-1, 2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid (R) - 1- (4-Amino-3-chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester sulfate ( 2g), characterized in that it has the characteristic values d = 5.98 Å, 5.78 Å, 5.37 Å, 4.24 Å and 4.02 Å among others in the X-ray powder diagram.

According to the findings shown in Table 12a, the present invention relates to crystalline 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / 1, 3-benzdiazepin-3-yl) - ( 1 R) - 1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxo ethyl ester hydrobromide (3a, polymorph 1) , characterized in that it has in the X-ray powder diagram, among others, the characteristic values d = 7.86 Ä, 6.18 Ä, 5.81 Ä, 4.66 Ä and 4.06 Ä.

According to the findings shown in Table 12b, the present invention relates to crystalline 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / 1, 3-benzadiazepin-3-yl) - ( 1R) - 1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester hydrobromide (3a, polymorph 2) , characterized in that it has in the X-ray powder diagram among others the characteristic values d = 25.99 Å, 7.73 Å, 7.10 Å, 6.05 Å, 5.89 Å, 4.28 Å and 3.92 Å.

According to the findings shown in Table 13a, the present invention relates to crystalline 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / 1, 3-benzdiazepin-3-yl) - ( 1 R) - 1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester hydrochloride (3b, polymorph 1) , characterized in that it has in the X-ray powder diagram, among others, the characteristic values d = 7.68 Ä, 6.15 Ä, 5.79 Ä, 4.64 Ä, 4.15 Ä and 4.03 Ä.

According to the findings shown in Table 13b, the present invention relates to crystalline 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / 1, 3-benzdiazepin-3-yl) - (1R) - 1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester hydrochloride (3b, polymorph 2 ), characterized in that it has in the X-ray powder diagram, among others, the characteristic values d = 7.74 Ä, 7.13 Ä, 6.00 Ä, 5.88 Ä and 4.22 Å.

According to the findings shown in Table 14, the present invention relates to crystalline 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / 1, 3-benzdiazepin-3-yl) - ( 1 R) - 1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxo ethyl ester phosphate (3c), characterized in that in the X-ray powder diagram it has among others the characteristic values d = 8.90 Å, 5.53 Å, 5.15 Å, 4.83 Å and 4.63 Å.

According to the findings shown in Table 15, the present invention relates to crystalline 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / 1, 3-benzdiazepin-3-yl) - ( 1 R) - 1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester (2R, 3R) -2 , 3-Dihydroxybutandioat (3d), characterized in that it has in the X-ray powder diagram, among others, the characteristic values d = 10.02 Ä, 8.90 Ä, 5.54 Ä, 5.20 Ä, 4.88 Ä and 4.67 Ä.

According to the findings shown in Table 16, the present invention relates to crystalline 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / 1, 3-benzdiazepin-3-yl) - ( 1 R) - 1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester (2S, 3S) -2 , 3-Dihydroxybutandioat (3e), characterized in that it has in the X-ray powder diagram, among others, the characteristic values d = 8.97 Ä, 5.57 Ä, 5.17 Ä, 4.87 Ä and 4.65 Ä.

According to the findings shown in Table 17, the present invention relates to crystalline 4- (2-oxo-1, 2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid (R) - 1- (4-hydroxy-3,5-dimethylbenzyl) -2-oxo-2- [4- (tetrahydropyran-4-yl) piperazin-1-yl] ethyl ester fumarate (4a), characterized that in the X-ray powder diagram it has among others the characteristic values d = 9.01 A, 6.30 A, 5.26 A, 5.07 A, 4.72 A and 4.52 A. According to the findings shown in Table 18, the present invention relates to crystalline 4- (2-oxo-1, 2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid (R) - 1- (4-hydroxy-3,5-dimethylbenzyl) -2-oxo-2- [4- (tetrahydropyran-4-yl) piperazin-1-yl] ethyl ester sulfate (4b), characterized that in the X-ray powder diagram it has among others the characteristic values d = 12.79 Å, 10.80 Å, 5.23 Å, 4.65 Å and 4.18 Å.

According to the findings shown in Table 19, the present invention relates to crystalline (S) -2- (4-amino-3-chloro-5-trifluoromethyl-benzyl) -1 - [4- (4-methylpiperazin-1-yl) - piperidin-1-yl] -4- [4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidin-1-yl] -butane-1, 4-dione hydrochloride pentahydrate (5a), characterized in that it has in the X-ray powder diagram, among others, the characteristic values d = 7.29 Ä, 7.2 Ä, 5.84 Ä, 4.42 Ä and 4.1 1 Ä.

According to the findings shown in Table 20, the present invention relates to crystalline (S) -2- (4-amino-3-chloro-5-trifluoromethyl-benzyl) -1 - [4- (4-methylpiperazin-1-yl) - piperidin-1-yl] -4- [4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidin-1-yl] -butane-1, 4-dione (2S, 3S) -2,3-dihydroxybutanedioate (5b), characterized in that it has in the X-ray powder diagram, among others, the characteristic values d = 10.21 Ä, 5.67 Ä, 4.7 Ä, 4.51 Ä and 4.14 Ä.

According to the findings shown in Table 21, the present invention relates to crystalline (S) -2- (4-amino-3-chloro-5-trifluoromethyl-benzyl) -1 - [4- (4-methylpiperazin-1-yl) - piperidin-1-yl] -4- [4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidin-1-yl] -butane-1, 4-dione hydrobromide pentahydrate (5c), characterized in that it has in the X-ray powder diagram, among others, the characteristic values d = 7.22 Å, 5.83 Å, 4.65 Å, 4.52 Å, 4.12 Å and 3.75 Å.

According to the findings shown in Table 22, the present invention relates to crystalline 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid {(R) -1- (3,4-diethyl-benzyl) -2- [4- (1-methylpiperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl} -amide-dimaleinate (6a) , characterized in that it has in the X-ray powder diagram, among others, the characteristic values d = 21.21 Ä, 9.99 Ä, 5.52 Ä, 5.33 Ä, 4.81 Ä and 3.99 Ä. According to the findings shown in Table 23, the present invention relates to crystalline 4- (2-oxo-1, 2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid {(/? ) -1- (3,4-diethylbenzyl) -2- [4- (1-methyl-piperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl} -amide-p-toluenesulfonate (6b), characterized in that it has in the X-ray powder diagram among others the characteristic values d = 25.57 Å, 8.59 Å, 7.61 Å, 7.04 Å, 6.19 Å and 5.25 Å.

According to the findings shown in Table 24, the present invention relates to crystalline 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid {(/? ) -1- (3,4-diethyl-benzyl) -2- [4- (1-methyl-piperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl} -amide-benzenesulfonate (6c ), characterized in that in the X-ray powder diagram it has among others the characteristic values d = 10.53 Å, 6.68 Å, 5.87 Å, 5.10 Å and 5.00 Å.

According to the findings shown in Table 25, the present invention relates to crystalline 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid {(R) 1- (3,4-diethyl-benzyl) -2- [4- (1-methylpiperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl} -amide-naphthalene-1, 5-disulfonate (6d), characterized in that, in the X-ray powder diagram, it has, among other things, the characteristic values d = 8.47 A, 7.15 A, 6.95 A, 5.29 A,

4.41 Ä, 4.07 Ä and 3.47 Ä.

According to the findings shown in Table 26, the present invention relates to crystalline 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid {(ft) -1- (3,4-diethyl-benzyl) -2- [4- (1-methyl-piperidin-4-yl) -piperazine-1-yl] -2-oxo-ethyl} -amide-naphthalene-2 sulfonate (6e), characterized in that, in the X-ray powder diagram, it has, among other things, the characteristic values d = 9.93 Å, 8.75 Å, 8.22 Å, 7.43 Å, 6.21 Å,

4.42 Ä and 4.23 Ä.

Methods of Preparation

As an example of a preferred preparation process according to the present invention, the preparation of the crystalline salt of the invention 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / - 1, 3-benzdiazepine-3 -yl) - (1R) - 1 - [(4-hydroxy-3,5-dimethyl- phenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester (2R, 3 /?) -2,3-dihydroxybutanedioate (3d), comprising the following steps :

(a) Mixing the base 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / -1,3-benzodiazepin-3-yl) - (1R) -1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester with a first solvent at room temperature and then heating the resulting suspension;

(b) adding a second solvent and then heating the reaction mixture;

(c) dropwise adding a concentrated solution of (L) - (+) - tartaric acid in water;

(d) slowly cooling the reaction mixture, filtering off and drying the crystals formed.

Preparation of the starting compound 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / -1,3-benzodiazepin-3-yl) - (1R) - 1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester of the formula II

is described in International Patent Application PCT / EP2005 / 003094.

According to the invention, the solvent used in step (a) is methanol, ethanol, propanol, isopropanol or a mixture of these solvents, ethanol or isopropanol or a 1: 1 mixture of ethanol and isopropanol being preferred according to the invention. The solvent in step (a) is used in an amount of 2 to 5 ml / mmol of base used, preferably in an amount of 3 to 4 ml / mmol of base used.

The suspension formed in step (a) is then heated to a temperature of 50 to 60 ° C.

According to the invention, the solvent used in step (b) is methanol, ethanol, propanol, isopropanol or a mixture of these solvents, ethanol or isopropanol or a 1: 1 mixture of ethanol and isopropanol being preferred according to the invention.

The solvent in step (b) is added in an amount of 2 to 5 in L / mmol of base used, preferably in an amount of 3 to 4 mL / mmol of base used.

The reaction mixture obtained in step (b) is then heated to a temperature of 70 to 80 ° C, preferably to a temperature of 74 to 76 ° C, heated.

According to the invention, the solvent used in step (a) is ethanol and the solvent used in step (b) is isopropanol.

The solvent used in step (c) is an amount of water equivalent to the amount of tartaric acid used. The water is used in an amount of 0.9 to 1.1 g / g of tartaric acid, preferably in an amount of 1.0 g / g of tartaric acid used.

According to the invention, 0.9 eq to 1.1 eq, preferably 1.0 eq, of the acid are used in step (c), in each case based on the amount of base used.

To accelerate the crystallization process, the solution formed in step (c) can be seeded with the desired form of the tartrate (3d).

Corresponding preparation processes for each of the abovementioned salts are carried out in the experimental part below. The described production methods are also industrially applicable for the production of large amounts of substance.

A third object of the present invention is its use as a drug because of the pharmaceutical activity of the crystalline salts.

INDICATIONS

Because of their pharmacological properties, the compounds according to the invention and their salts with physiologically tolerated acids are thus suitable for the acute and prophylactic treatment of headaches, in particular migraine, cluster headache and tension-type headaches. Furthermore, the compounds according to the invention also have a positive influence on the following diseases: non-insulin-dependent diabetes mellitus ("NIDDM"), cardiovascular diseases, morphine tolerance, Clostridium toxin-related diarrheal diseases, skin disorders, especially thermal and radiation-related skin damage including sunburn, skin, prurigo, pruriginous toxidermias as well as severe itching, inflammatory diseases, eg inflammatory joint diseases (osteoarthritis, rheumatoid arthritis, neurogenic arthritis), generalized soft tissue rheumatism (fibromyalgia), neurogenic inflammations of the oral mucosa, inflammatory lung diseases, allergic rhinitis, asthma, COPD, diseases associated with excessive vasodilation and consequent reduced tissue perfusion, e.g. Shock and sepsis, chronic pain disorders, e.g. diabetic neuropathies, chemotherapy-induced neuropathies, HIV-induced neuropathies, postherpetic neuropathies by tissue trauma-induced neuropathies, trigeminal neuralgia, temporomandibular dysfunctions, complex regional pain syndrome (CRPS), back pain, and visceral diseases, preferably irritable bowel syndrome (IBS) and inflammatory bowel syndrome. In addition, the compounds according to the invention have a soothing effect on pain conditions in general.

The symptoms of menopausal, caused by vasodilation and increased blood flow hot flushes of estrogen-deficient women and hormone-treated prostate cancer patients and castrates is the present CGRP antagonists Preventive and acute-therapeutically favorably influenced treatment application, whereby this therapy approach is characterized by side effect poverty before the hormone substitution.

The compounds according to the invention are preferably suitable for the acute and prophylactic treatment of migraine and cluster headache, for the treatment of irritable bowel syndrome (IBS) and for the preventive and acute therapeutic treatment of hot flushes of estrogen-deficient women.

The dosage required to achieve a corresponding effect is advantageously from 0.0001 to 3 mg / kg body weight, preferably from 0.01 to 1 mg / kg body weight, when administered intravenously or subcutaneously, and 0.01 to 10 mg / kg body weight when administered orally, nasally or by inhalation. preferably 0.1 to 10 mg / kg of body weight, one to three times daily.

If treatment with CGRP antagonists or / and CGRP release inhibitors is made in addition to conventional hormone replacement, it is recommended that the dosages given above be reduced, with the dosage then being 1/5 of the above lower limits up to 1/1 of the above may be upper limits.

Another object of the invention is the use of the compounds of the invention as valuable tools for generating and purifying (affinity chromatography) of antibodies and, after appropriate radioactive labeling, for example by tritiation of suitable precursors, for example by catalytic hydrogenation with trithium or replacement of halogen atoms by tritium, in RIA and ELISA assays and as diagnostic and analytical tools in neurotransmitter research.

COMBINATIONS

Possible combinations of agents include antiemetics, prokinetics, neuroleptics, antidepressants, neurokinin antagonists, anticonvulsants, histamine H1 receptor antagonists, β-blockers, α-agonists and α-antagonists, ergot alkaloids, weak analgesics, nonsteroidal anti-inflammatory drugs, corticosteroids, calcium Antagonists, 5-HT _{1B /} i _D agonists or other antimigraine agents that co-exist with a or several inert customary carriers and / or diluents, for example with corn starch, milk sugar, cane sugar, microcrystalline cellulose, magnesium stearate, polyvinyl pyrrolidone, citric acid, tartaric acid, water, water / ethanol, water / glycerol, water / sorbitol, water / polyethylene glycol, propylene glycol, Cetylstearylalkohol, carboxymethylcellulose or fatty substances such as hard fat or their suitable mixtures can be incorporated into common pharmaceutical preparations such as tablets, dragees, capsules, powders, suspensions, solutions, metered aerosols or suppositories.

For the abovementioned combinations, the non-steroidal anti-inflammatory drugs aceclofenac, acemetacin, acetylsalicylic acid, acetaminophen (paracetamol), azathioprine, diclofenac, diflunisal, fenbufen, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, leflunomide, lornoxicam, mefenamic acid are thus used as further active substances , Naproxen, phenylbutazone, piroxicam, sulfasalazine, zomepirac or their pharmaceutically acceptable salts as well as meloxicam and other selective COX2 inhibitors such as rofecoxib, valdecoxib, parecoxib, etoricoxib and celecoxib, as well as substances which inhibit earlier or later steps in the prostaglandin Inhibit synthesis or prostaglandin receptor antagonists such as EP2 receptor antagonists and I P receptor antagonists.

Furthermore, ergotamine, dihydroergotamine, metoclopramide, domperidone, diphenhydramine, cyclizine, promethazine, chlorpromazine, vigabatrin, timolol, isomethepten, pizotifen, botox, gabapentin, pregabalin, duloxetine, topiramate, riboflavin, montelukast, lisinopril, micardis, prochlorperazine, dexamethasone, flunarizine, dextropropoxyphene, meperidine, metoprolol, propranolol, nadolol, atenolol, clonidine, indoramin, carbamazepine, phenytoin, valproate, amitryptiline, imipramine, venlafaxine, lidocaine or diltiazem and other 5-HT _{1B / D} i agonists such as almotriptan, Eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan and zolmitriptan.

In addition, CGRP antagonists with vanilloid receptor antagonists such as VR-1 antagonists, glutamate receptor antagonists such as mGlu5 receptor antagonists, Glu receptor antagonists, iGluδ receptor antagonists, AMPA receptor antagonists, purine receptor blockers such as P2X3 Antagonists, NO synthase inhibitors such as iNOS inhibitors, calcium channel blockers such as PQ-type blockers, N-type blockers, Potassium channel openers such as KCNQ channel openers, sodium channel blockers such as PN3 channel blockers, NMDA receptor antagonists, acid-sensing ion channel antagonists such as ASIC3 antagonists, bradykinin receptor antagonists such as B1 receptor antagonists, cannabinoid receptor agonists such as CB2 Agonists, CB1 agonists, somatostatin receptor agonists, such as sst2 receptor agonists.

The dose for these active substances is expediently 1/5 of the usually recommended lowest dosage up to 1/1 of the normally recommended dosage, so for example 20 to 100 mg sumatriptan.

PRESENTATIONS

The compounds according to the invention may be administered either alone or optionally in combination with other active substances for the treatment of migraine intravenously, subcutaneously, intramuscularly, intraarticularly, intrarectally, intranasally, by inhalation, topically, transdermally or orally, in particular aerosol formulations being suitable for inhalation. The combinations may be administered either simultaneously or sequentially.

Suitable application forms are, for example, tablets, capsules, solutions, juices, emulsions or inhalable powders or aerosols. In this case, the proportion of the pharmaceutically active compound (s) in each case in the range of 0.1 to 90 wt .-%, preferably 0.5 to 50 wt .-% of the total composition, i. in amounts sufficient to achieve the above dosage range.

Oral administration may be in the form of a tablet, as a powder, as a powder in a capsule (e.g., hard gelatin capsule), as a solution or suspension. In the case of an inhalative administration, the active substance combination can be carried out as a powder, as an aqueous or aqueous-ethanolic solution or by means of a propellant gas formulation.

Therefore, pharmaceutical formulations are preferably characterized by the content of one or more of the compounds of the invention. It is particularly preferred if the compounds of the formula I are administered orally, it is particularly preferred if the administration takes place once or twice daily. Corresponding tablets can be prepared, for example, by mixing the active substance (s) with known auxiliaries, for example inert diluents, such as calcium carbonate, calcium phosphate or lactose, disintegrants, such as corn starch or alginic acid, binders, such as starch or gelatin, lubricants, such as magnesium stearate or talc, and / or means for achieving the depot effect, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate. The tablets can also consist of several layers.

Coated tablets can accordingly be produced by coating cores produced analogously to the tablets with agents customarily used in tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar. To achieve a depot effect or to avoid incompatibilities, the core can also consist of several layers. Likewise, the

Drageum cover to achieve a depot effect consist of several layers wherein the above mentioned in the tablets excipients can be used.

Juices of the active compounds or active compound combinations according to the invention may additionally contain a sweetening agent, such as saccharin, cyclamate, glycerol or sugar, and a taste-improving agent, e.g. Flavorings such as vanillin or orange extract. They may also contain suspending aids or thickening agents, such as sodium carboxymethylcellulose, wetting agents, for example condensation products of fatty alcohols with ethylene oxide, or protective agents, such as p-hydroxybenzoates.

The capsules containing one or more active ingredients or combinations of active substances can be prepared, for example, by mixing the active ingredients with inert carriers, such as lactose or sorbitol, and encapsulating them in gelatine capsules. Suitable suppositories can be prepared, for example, by mixing with suitable carriers, such as neutral fats or polyethylene glycol or its derivatives. AIs are, for example, water, pharmaceutically acceptable organic solvents, such as paraffins (eg petroleum fractions), oils of vegetable origin (eg peanut or sesame oil), mono- or polyfunctional alcohols (eg ethanol or glycerol), carriers such as natural minerals (eg kaolin, Clays, talc, chalk) synthetic minerals (eg finely divided silicic acid and silicates), sugars (eg pipe, milk and dextrose) emulsifiers (eg lignin, liquors, methylcellulose, starch and polyvinylpyrrolidone) and lubricants (eg magnesium stearate, talc, stearic acid and Sodium lauryl sulfate).

In the case of oral administration, of course, the tablets may also contain additives other than those mentioned. Sodium citrate, calcium carbonate and dicalcium phosphate together with various additives such as starch, preferably potato starch, gelatin and the like. Further, lubricants such as magnesium stearate, sodium lauryl sulfate and talc may be used for tableting. In the case of aqueous suspensions, the active ingredients may be added to the abovementioned excipients with various flavor enhancers or dyes.

It is likewise preferred if the compounds according to the invention are administered by inhalation, it is particularly preferred if the administration takes place once or twice daily. For this purpose, the compounds according to the invention must be provided in inhalable dosage forms. Suitable inhalable dosage forms are inhalable powders, propellant-containing metered-dose inhalers or propellant-free inhalable solutions, which may be present in admixture with customary physiologically compatible excipients.

EXPERIMENTAL PART

The compounds of general formula I can be prepared by methods known in principle. The methods listed in the "Handbook of Pharmaceutical Salts" (Eds. P. Heinrich Stahl, Camille G. Wermuth, Wiley-VHC 2002) have proven particularly useful. example 1

1 - [4-Amino-3,5-dibromo-Λ / - [[4- (2,3,4,5-tetrahydro-2 (1 H) -oxo-1,3-benzodiazepin-3-yl] - 1-piperidinyl] carbonyl] -D-phenylalanyl] -4- (1-piperidinyl) -piperidine-p-toluenesulfonate (1a)

1.52 g (2.0 mmol) of 1- [4-amino-3,5-dibromo-Λ / - [[4- (2,3,4,5-tetrahydro-2 (1 / - /) - oxo-1,3] benzodiazepin-3-yl) -1-piperidinyl] carbonyl] - (D) -phenylalanyl] -4 - (- 1-piperidinyl) -pipeιϊdin are suspended in 20 ml of ethanol at 50 ° C. and treated portionwise with 380 mg (2.0 mmol) of p-toluenesulfonic acid monohydrate. The mixture is heated to 65 ° C, producing a clear solution. Upon cooling to 50 ° C, a white precipitate forms. The suspension is stirred for 12 hours at room temperature and filtered. The solid is washed with 3 ml of ethanol and dried at 45 ° C for 12 hours. Yield: 1.41 g (76% of theory)

Example 2

1 - [4-Amino-3,5-dibromo-Λ / - [[4- (2,3,4,5-tetrahydro-2 (1 H) -oxo-1,3-benzodiazepin-3-yl] - 1-piperidinyl] carbonyl] -D-phenylalanyl] -4- (1-piperidinyl) piperidine benzenesulfonate (1 b)

7.6 g (10.0 mmol) of 1- [4-amino-3,5-dibromo-Λ / - [[4- (2,3,4,5-tetrahydro-2 (1 / - /) - oxo-1,3] benzodiazepin-3-yl) -1-piperidinyl] carbonyl] - (D) -phenylalanyl] -4 - (- 1-piperidinyl) -piperidine are suspended in 100 ml of ethanol at 50 ° C. and treated portionwise with 1.6 g of ( 10.0 mmol) benzene sulfonic acid added. After addition of 0.18 ml of water, the mixture is cooled to 45 ° C and stirred for 8 hours at this temperature. The mixture is then stirred for 7 days at 40 ° C, forming a precipitate. Thereafter, the suspension formed is stirred for 7 days at 35 ° C, 7 days at 30 ° C and 3 days at room temperature. The solid formed is filtered off, washed with 15 ml of ethanol and dried at 45 ° C for 12 hours. Yield: 5.08 g (55% of theory)

Example 3

1 - [4-Amino-3,5-dibromo-Λ / - [[4- (2,3,4,5-tetrahydro-2 (1 H) -oxo-1,3-benzodiazepin-3-yl] - 1-piperidinyl] carbonyl] -D-phenylalanyl] -4- (1-piperidinyl) piperidine maleate (1c)

1.52 g (2.0 mmol) of 1- [4-amino-3,5-dibromo- / V - [[4- (2,3,4,5-tetrahydro-2 (1 H) -oxo-1,3-benzo - diazepin-3-yl) -1-piperidinyl] carbonyl] - (D) -phenylalanyl] -4 - (- 1-piperidinyl) -piperidine are suspended in 20 ml of ethanol at 60 ° C and added portionwise with 0.23 g (2.0 mmol ) Maleic acid. The mixture is cooled to room temperature and stirred for 3 days. The solid formed is filtered off, washed with 3 ml of ethanol and dried at 45 ° C. for 12 hours. Yield: 0.82 g (47% of theory)

Example 4

4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - (I?) - 1 - (4-amino-3-chloro) 5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester dimaleinate (2a)

1.0 g (1.39 mmol) of 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - (I?) - 1- ( 4-amino-3-chloro-5-trifluoromethylbenzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester are dissolved in 10 ml Dissolved ethanol at room temperature and treated with 322 mg (2.78 mmol) of maleic acid. The mixture is heated to 70 ° C, forming a white precipitate. The suspension is cooled to room temperature over 8 hours and filtered at 5 ° C. The isolated crystals are dried at 50 ° C for 12 hours. Yield: 1.08 g (82% of theory)

Example 5

4- (2-Oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid- (R) -1- (4-amino-3-chloro-4-chloro-4-enyl) -5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester hydrobromide (2b)

0.5 g (0.69 mmol) of 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - (I?) - 1- ( 4-amino-3-chloro-5-trifluoromethylbenzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester are dissolved in 5 ml Dissolved ethanol at room temperature and mixed with 78 .mu.l of hydrobromic acid (48% in water). The mixture is heated to 70 ° C, forming a light yellow solution. This solution is stirred for 3 days at 50 ° C, whereby a white precipitate forms. After cooling to room temperature, the solid formed is filtered off and dried at 40 ° C for 12 hours. Yield: 70 mg (13% of theory)

Example 6

4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - (I?) - 1 - (4-amino-3-chloro) 5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester dihydrobromide (2c)

0.5 g of 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - (I?) - 1 - (4-amino-3-) chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester (chemical purity: 85%, 0.59 mmol) are dissolved in Dissolve 5 ml of ethanol at room temperature and add 235 .mu.l hydrobromic acid (30% in glacial acetic acid), whereupon immediately precipitates a white precipitate. The suspension is stirred for 5 hours at room temperature, diluted with a little ethanol and filtered. The isolated solid is dried at 70 ° C for 12 hours. Yield: 480 mg (92% of theory)

Example 7

4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - (I?) - 1 - (4-amino-3-chloro) 5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester hydrochloride (2d)

0.5 g (0.69 mmol) of 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - (I?) - 1- ( 4-amino-3-chloro-5-trifluoromethylbenzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester are dissolved in 5 ml Isopropanol dissolved at room temperature. After addition of 95.2 μl of hydrochloric acid (12.4 mol / l in ethanol) spontaneously forms a white precipitate. After 12 hours at room temperature, the precipitate formed is filtered off and dried at 70 ° C. Yield: 0.19 g (41% of theory)

Example 8

4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - (I?) - 1 - (4-amino-3-chloro) 5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester difumarate (2e)

2.5 g (2.95 mmol) of 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid- (R) -1- (4 -amino-3-chloro-5-trifluoromethylbenzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester are dissolved in 25 ml of ethanol Dissolved at room temperature, with 685 mg (5.9 mmol) of fumaric acid and heated to 45 ° C. It forms a tough suspension, which is diluted by the addition of 15 ml of ethanol. The mixture is heated to 70 ° C, forming a white precipitate. The formed suspension is with diluted further 5 ml of ethanol, cooled to 26 ° C and filtered. The isolated solid is dried at 60 ° C for 12 hours. Yield: 2.49 g (89% of theory)

Example 9

4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - (I?) - 1 - (4-amino-3-chloro) 5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester disuccinate (2f)

0.5 g (0.69 mmol) of 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid- (R) -1- (4 -amino-3-chloro-5-trifluoromethylbenzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester are dissolved in 5 ml of isopropanol dissolved at room temperature, treated with 82 mg (0.69 mmol) of succinic acid and heated to 50 ° C. After 18 hours at 50 ° C, a white precipitate has formed. The suspension is cooled to 30 ° C, filtered, washed with isopropanol and dried. Yield: 0.24 g (36% of theory)

Example 10

4- (2-Oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid- (R) -1- (4-amino-3-chloro-5 -trifluoromethylbenzyl) -2- [4- (4-methylpiperazin-1-yl) piperidin-1-yl] -2-oxoethyl ester sulfate (2g)

0.5 g (0.69 mmol) of 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - (I?) - 1- ( 4-amino-3-chloro-5-trifluoromethylbenzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester are dissolved in 10 ml Dissolved methanol at room temperature. After addition of 100 .mu.l of sulfuric acid (48% in water), the mixture is stirred for 3 hours at room temperature. After evaporation of about 5 ml of methanol, 1 ml terf-butyl methyl ether is added, whereby an oil separates. After removal of the supernatant solvent, the residue is treated with 5 ml of acetone, crystallization commencing. The precipitate formed is filtered and dried at 30 ° C for 12 hours. Yield: 0.26 g (46% of theory)

Example 11

1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / - 1, 3-benzdiazepin-3-yl) - (1 R) -1 - [(4-hydroxybenzyl) 3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester hydrobromide (3a)

(11a) polymorph 1; Form B

0.5 g (0.79 mmol) 1-piperidinecarboxylic acid 4- (1,2,4,5-tetrahydro-2-oxo-3 / - / -1,3-benzodiazepin-3-yl) - (1 /?) -1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester are suspended at room temperature in 5 ml of acetone. The formed suspension is heated to 52 ° C and treated with 1.0 ml of ethanol, with a clear Solution arises. After addition of 157 .mu.l hydrobromic acid (30% in glacial acetic acid), the solution is cooled to room temperature over 5 hours. The solution is mixed with 2.5 ml of n-butyl acetate, causing turbidity. The resulting suspension is heated to 60 ° C for 20 minutes, then cooled to 45 ° C and stirred at this temperature for 12 hours. After cooling to room temperature, the precipitate formed is filtered off, washed with acetone and dried at 80 ° C for 6 hours. Yield: 520 mg (92% of theory)

(1 1 b) polymorph 2; Form A 0.5 g (0.79 mmol) of 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / -1,3-benzodiazepin-3-yl) - (1 R ) - 1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester are suspended in 5 ml of n-propanol at room temperature and heated to 70 ° C. After addition of 157 .mu.l of hydrobromic acid (30% in glacial acetic acid), the mixture is stirred for 1 hour at 70.degree. C. and for 20 hours at 40.degree. Subsequently, the formed suspension is cooled to room temperature, stirred for 5 hours and filtered. The residue is dried for 4 hours at 80.degree. Yield: 460 mg (72% of theory)

Example 12

1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / - 1, 3-benzdiazepin-3-yl) - (1 R) -1 - [(4-hydroxybenzyl) 3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester hydrochloride (3b)

(12a) polymorph 1; Form B

0.5 g (0.79 mmol) of 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / -1,3-benzodiazepin-3-yl) - (1R) - 1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperid dinyl] -2-oxoethylester are dissolved in 5 ml of isopropanol at 70 ° C and treated with 69.2 .mu.l of hydrochloric acid (11.4 mol / l in ethanol), with a clouding occurs. After 1.5 hours at 70 ° C, 3 ml of isopropanol are added to dilute the suspension formed. The mixture is gradually cooled to room temperature within 2.5 hours, filtered and dried at 55 ° C for 12 hours. For complete removal of solvent, the solid is dried for a further 6 hours at 65 ° C and 5 hours at 80 ° C. Yield: 470 mg (84% of theory)

(12b) polymorph 2; Form A

0.5 g (0.79 mmol) of 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / -1,3-benzodiazepin-3-yl) - (1R) - 1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester are dissolved in 5 ml of ethanol at room temperature and treated with 65.3 μl Hydrochloric acid (37% in water). After 2 hours at room temperature, terf-butylmethyl ether is added dropwise until turbidity occurs. After a further 2 hours at room temperature, the formed white precipitate is filtered off, washed with terf-butyl methyl ether and dried at 40 ° C for 12 hours. Yield: 370 mg (70% of theory)

Example 13

1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / - 1, 3-benzdiazepin-3-yl) - (1 R) -1 - [(4-hydroxybenzyl) 3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester phosphate (3c)

1.0 g (1.58 mmol) of 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / -1,3-benzodiazepin-3-yl) - (1R) A - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperid dinyl] -2-oxoethyl ester are dissolved in 8.9 ml of boiling ethanol and treated with a solution of 106 .mu.l of phosphoric acid (85% in water) in 1.06 ml of ethanol. The mixture is stirred for 2 hours at 72 ° C, forming a white suspension. After cooling, the suspension is stirred for 12 hours at room temperature. The crystals formed are filtered off and dried at 40 ° C. for 12 hours. Yield: 520 mg (44% of theory)

Example 14

1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / - 1, 3-benzdiazepin-3-yl) - (1 R) -1 - [(4-hydroxybenzyl) 3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester (2R, 3R) -2,3-dihydroxybutanedioate (3d)

TO

39.4 g (57.8 mmol, 93%)) of 1-piperidinecarboxylic acid 4- (1,2,4,5-tetrahydro-2-oxo-3 / - / -1,3-benzodiazepin-3-yl) - (1 R) - 1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester are taken up in 197 ml of ethanol at room temperature. The mixture is heated to 70 ° C, with 197 ml of isopropanol are added. At 75 ° C., a solution of 10.25 g (67.6 mmol) of (L) - (+) - tartaric acid in 10.25 ml of water is added dropwise. After seeding with the desired polymorph, the mixture is cooled to 18 ° C within 4 hours. The crystals formed are filtered off, washed with ethanol and dried. Yield: 38.8 g (84% of theory)

Example 15 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / - 1, 3-benzdiazepin-3-yl) - (1 R) -1 - [(4-hydroxybenzyl) 3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester (2S, 3S) -2,3-dihydroxybutanedioate (3e)

2.0 g (3.16 mmol) of 1-piperidinecarboxylic acid 4- (1,2,4,5-tetrahydro-2-oxo-3 / - / -1,3-benzodiazepin-3-yl) - (1R) - Dissolve 1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester in 15 ml of boiling isopropanol. 479 mg (3.16 mmol) of (D) - (-) - tartaric acid are dissolved in 5 ml of boiling isopropanol and added dropwise hot to the isopropanolic solution of the base. The mixture is refluxed for 1.5 hours until a white suspension has formed. After cooling, the suspension is stirred for 1 hour at room temperature. The crystals formed are filtered off and dried at 40 ° C. for 12 hours. Yield: 2.1 g (81% of theory)

Example 16

4- (2-Oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid - (I?) - 1 - (4-hydroxy-3, 5-dimethyl-benzyl) -2-oxo-2- [4- (tetrahydro-pyran-4-yl) -piperazin-1-yl] -ethyl ester fumarate (4a)

0.25 g (0.39 mmol) of 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / -1,3-benzdiazepin-3-yl) - (1R) - 1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-tetrahydropyranyl) -1-piperazinyl] -2-oxoethyl ester and 46.7 mg (0.39 mmol) of fumaric acid are dissolved in 2.5 ml of ethanol and Dissolve 4 drops of water at 70 ° C. The mixture is cooled to room temperature over 12 hours, forming a colorless suspension. The crystals formed are filtered off, washed with ethanol and dried at 40 ° C. for 12 hours. Yield: 170 mg (57% of theory)

Example 17

4- (2-Oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid - (I?) - 1 - (4-hydroxy-3, 5-dimethyl-benzyl) -2-oxo-2- [4- (tetrahydro-pyran-4-yl) -piperazin-1-yl] -ethyl ester sulfate (4b)

0.25 g (0.39 mmol) of 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / -1,3-benzdiazepin-3-yl) - (1R) - Dissolve 1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-tetrahydropyranyl) -1-piperazinyl] -2-oxoethyl ester in 1.75 ml of isopropanol and heat to 70 ° C. 22.2 μl of sulfuric acid (95% in water) are added at this temperature to form a colorless precipitate. The resulting suspension is cooled to room temperature over 2.5 hours. The crystals formed are filtered off, washed with isopropanol and dried at 45 ° C. for 12 hours. Yield: 260 mg (90% of theory)

Example 18 (S) -2- (4-amino-3-chloro-5-trifluoromethyl-benzyl) -1 - [4- (4-methyl-piperazin-1-yl) -piperidine-1 ^■ yl] -4- [4 - (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidin-1-yl] -butane-1,4-dione hydrochloride pentahydrate (5a)

3.0 g (4.2 mmol) of (S) -2- (4-amino-3-chloro-5-trifluoromethyl-benzyl) -1- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl ] -4- [4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidin-1-yl] -butane-1,4-dione are prepared in 3 Dissolved acetone and treated with a solution of 4.2 ml of hydrochloric acid (1 mol / l in water) in 22.8 ml of water. The mixture is heated to reflux and cooled to room temperature over 12 hours. The resulting solid is filtered off and dried at 40 ° C for 12 hours. Yield: 3.0 g (85% of theory)

Example 19

(S) -2- (4-Amino-3-chloro-5-trifluoromethyl-benzyl) -1 - [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -4- [4 - (2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidin-1-yl] -butane-1,4-dione (2S, 3S) -2, 3-dihydroxybutanedioate (5b)

0.5 g (0.7 mmol) of (S) -2- (4-amino-3-chloro-5-trifluoromethyl-benzyl) -1- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl ] -4- [4- (2-oxo-1, 2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidin-1-yl] -butane-1,4-dione and 209 mg (1.4 mmol) of (D) - (-) - tartaric acid are dissolved in 5 ml of water and heated to reflux. The solution is then cooled to room temperature over 12 hours. The resulting solid is filtered off and dried at 40 ° C for 12 hours. Yield: 0.5 g (71% of theory)

Example 20

(S) -2- (4-Amino-3-chloro-5-trifluoromethyl-benzyl) -1 - [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -4- [4 - (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidin-1-yl] -butane-1,4-dione hydrobromide pentahydrate (5c)

2.0 g (2.6 mmol) of (S) -2- (4-amino-3-chloro-5-trifluoromethyl-benzyl) -1- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl ] -4- [4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidin-1-yl] -butane-1,4-dione are reported in 20 Dissolved ml of isopropanol and treated at 50 ° C with 0.6 ml of hydrobromic acid (47% in water). The mixture is cooled to 4 ° C within 30 minutes. The solid formed is filtered off, washed with 5 ml of cold isopropanol and dried at 40 ° C. for 12 hours. Yield: 1.94 g (83% of theory)

Example 21

4- (2-Oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid {(/?) - 1 - (3,4-diethyl benzyl) -2- [4- (1-methyl-piperidin-4-yl) -piperazine-1-yl] -2-oxo-ethyl} -amide-dimaleinate (6a) .OH

0.5 g (0.76 mmol) of 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - {(/?) - 1- (3,4-diethyl-benzyl) -2- [4- (1-methylpiperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl} -amide and 88 mg (0.76 mmol) maleic acid are suspended in 10 ml of acetone and heated to reflux. 1 ml of methanol is added to this suspension, the substances completely dissolving. After addition of a further 5 ml of acetone, the solution is stirred for 2 days at room temperature. The solid formed on the glass wall is dissolved and a further 10 ml of acetone are added. The precipitate formed is filtered off and dried at 40 ° C for 12 hours. Yield: 20 mg (3% of theory)

Example 22

4- (2-Oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid {(/?) - 1 - (3,4-diethyl benzyl) -2- [4- (1-methyl-piperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl} -amide-p-toluene-sulfonate (6b)

0.2 g (0.30 mmol) of 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - {(R) -1- ( 3,4-diethyl-benzyl) -2- [4- (1-methylpiperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl} -amide and 57.8 mg (0.30 mmol) p- Toluene sulfonic acid are suspended in 10 ml of acetone and heated to reflux. To this suspension is added 1 ml of methanol, the Substance completely goes into solution. After cooling to room temperature, the solid formed is filtered off, washed with acetone and dried at 40 ° C for 12 hours. Yield: 120 mg (47% of theory)

Example 23

4- (2-Oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid {(/?) - 1 - (3,4-diethyl benzyl) -2- [4- (1-methylpiperidin-4-yl) piperazin-1-yl] -2-oxoethyl} amide benzene sulfonate (6c)

1.0 g (1.52 mmol) of 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - {(/?) - 1- (3,4-diethyl-benzyl) -2- [4- (1-methylpiperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl} -amide and 240 mg (1.52 mmol) benzenesulfonic acid are dissolved in 14 ml of boiling isopropanol. The solution is stirred for 24 hours at 50.degree. Thereafter, the temperature is reduced by 5 ° C after every 8 hours, forming a white precipitate. After 3 days and a final temperature of 25 ° C, the solid formed is filtered off, washed with 5 ml of isopropanol and dried at 50 ° C for 12 hours. Yield: 580 mg (47% of theory)

Example 24

4- (2-Oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid {(/?) - 1 - (3,4-diethyl -benzyl) -2- [4- (1-methylpiperidin-4-yl) piperazin-1-yl] -2-oxo-ethyl} -amide-naphthalene-1, 5-disulfonate (6d)

A solution of 1,427 g of naphthalene-1,5-disulfonic acid (4.95 mmol) in 70 ml of isopropanol is added to 3.25 g (4.94 mmol) of 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepine 3-yl) -piperidine-1-carboxylic acid - {(/?) - 1 - (3,4-diethyl-benzyl) -2- [4- (1-methyl-piperidin-4-yl) -piperazine-1 -yl] - 2-oxo-ethyl} -amide added and heated to 80 ° C. The now clear solution is cooled to room temperature, in which the temperature of the heating bath is lowered by 5 ° C after every 6 hours. The suspension thus formed is filtered, the isolated solid is dried at 40 ° C for 12 hours. Yield: 3.7 g (79% of theory)

Example 25

4- (2-Oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid {(/?) - 1 - (3,4-diethyl benzyl) -2- [4- (1-methyl-piperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl} -amide-naphthalene-2-sulfonate (6e)

0.25 g (0.38 mmol) 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - {(/?) - 1- (3,4-diethyl-benzyl) -2- [4- (1-methylpiperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl} -amide and 86.2 mg (0.38 mmol) naphthalene 2-sulfonic acid monohydrate are suspended in 5 ml of isopropanol and heated to reflux. The solution is cooled to room temperature within 5 days in 5 ° C increments and filtered. The isolated solid is washed with isopropanol and dried at 60 ° C for 12 hours. Yield: 150 mg (46% of theory)

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows the X-ray powder diffractogram of the crystalline compound 1- [4-amino-3,5-dibromo-Λ / - [[4- (2,3,4,5-tetrahydro-2 (1H) -oxo-1,3] benzodiazepin-3-yl) -1-piperidinyl] carbonyl] -D-phenylalanyl] -4- (1-piperidinyl) piperidine p-toluenesulfonate (1 a).

FIG. 2 shows the X-ray powder diffractogram of the crystalline compound 1- [4-amino-3,5-dibromo-Λ / - [[4- (2,3,4,5-tetrahydro-2 (1 / - /) -oxo-1] , 3-benzodiazepin-3-yl) -1-piperidinyl] - carbonyl] -D-phenylalanyl] -4- (1-piperidinyl) -piperidine-benzenesulfonate (1 b).

FIG. 3 shows the X-ray powder diffractogram of the crystalline compound 1- [4-amino-3,5-dibromo-Λ / - [[4- (2,3,4,5-tetrahydro-2 (1H) -oxo-1,3] benzodiazepin-3-yl) -1-piperidinyl] carbonyl] -D-phenylalanyl] -4- (1-piperidinyl) piperidine maleate (1c).

FIG. 4 shows the X-ray powder diffractogram of the crystalline compound 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid- (R) -1- (4 -amino-3-chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methyl-1-piperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl dimaleinate (2a).

FIG. 5 shows the X-ray powder diffractogram of the crystalline compound 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzdiazepin-3-yl) -piperidine-1-carboxylic acid- (R) -1- (4 -amino-3-chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester hydrobromide (2b).

FIG. 6 shows the X-ray powder diffractogram of the crystalline compound 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid (?) -1 ( 4-amino-3-chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester dihydrobromide (2c).

FIG. 7 shows the X-ray powder diffractogram of the crystalline compound 4- (2-oxo)

1, 2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid (R) -1- (4-amino-3-chloro) 5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester hydrochloride (2d).

FIG. 8 shows the X-ray powder diffractogram of the crystalline compound 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid (?) -1 ( 4-amino-3-chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester difumarate (2e).

FIG. 9 shows the X-ray powder diffractogram of the crystalline compound 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid- (R) -1- (4 -amino-3-chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester disuccinate (2f).

FIG. 10 shows the X-ray powder diffractogram of the crystalline compound 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - (I?) - 1 - ( 4-Amino-3-chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester sulfate (2g).

FIG. 1a shows the X-ray powder diffractogram of the crystalline compound 1-piperidinecarboxylic acid 4- (1,2,4,5-tetrahydro-2-oxo-3 / -1,3-benzdiazepin-3-yl) - (1 R) - 1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester hydrobromide (3a) polymorph 1.

FIG. 11b shows the X-ray powder diffractogram of the crystalline compound 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / 1, 3-benzdiazepin-3-yl) - ( 1 R) -1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester hydrobromide (3a) polymorph 2 ,

FIG. 12a shows the X-ray powder diffractogram of the crystalline compound 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / -1,3-benzdiazepin-3-yl) - (1 / ?) - 1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester hydrochloride (3b) polymorph 1. FIG. 12b shows the X-ray powder diffractogram of the crystalline compound 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / -1,3-benzdiazepin-3-yl) - (1R ) - 1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester hydro-chloride (3b) polymorph 2.

FIG. 13 shows the X-ray powder diffractogram of the crystalline compound 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / -1,3-benzdiazepin-3-yl) - (1R ) - 1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester phosphate (3c).

FIG. 14 shows the X-ray powder diffractogram of the crystalline compound 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / -1,3-benzdiazepin-3-yl) - (1R ) - 1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester (2R, 3R) -2,3-dihydroxybutanedioate (3d).

FIG. 15 shows the X-ray powder diffractogram of the crystalline compound 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / -1,3-benzdiazepin-3-yl) - (1R ) - 1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester (2S, 3S) -2,3-dihydroxybutanedioate (3e).

FIG. 16 shows the X-ray powder diffractogram of the crystalline compound 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid- (R) -1- (4 -hydroxy-3,5-dimethylbenzyl) -2-oxo-2- [4- (tetrahydropyran-4-yl) piperazin-1-yl] ethyl ester fumarate (4a).

FIG. 17 shows the X-ray powder diffractogram of the crystalline compound 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid- (R) -1- (4 -hydroxy-3,5-dimethyl-benzyl) -2-oxo-2- [4- (tetrahydropyran-4-yl) -piperazin-1-yl] -ethyl ester sulfate (4b).

FIG. 18 shows the X-ray powder diffractogram of the crystalline compound (S) -2- (4-amino-3-chloro-5-trifluoromethyl-benzyl) -1 - [4- (4-methylpiperazin-1-yl) -piperidine 1 -yl] -4- [4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidin-1-yl] -butane-1, 4- dione hydrochloride pentahydrate (5a). FIG. 19 shows the X-ray powder diffractogram of the crystalline compound (S) -2- (4-amino-3-chloro-5-trifluoromethyl-benzyl) -1 - [4- (4-methylpiperazin-1-yl) -piperidine 1 -yl] -4- [4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidin-1-yl] -butane-1, 4- dione (2S, 3S) -2,3-dihydroxybutanedioate (5b).

FIG. 20 shows the X-ray powder diffractogram of the crystalline compound (S) -2- (4-amino-3-chloro-5-trifluoromethylbenzyl) -1 - [4- (4-methylpiperazin-1-yl) piperidine 1 -yl] -4- [4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidin-1-yl] -butane-1, 4- dion hydrobromide pentahydrate (5c).

FIG. 21 shows the X-ray powder diffractogram of the crystalline compound 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid {(/?) - 1 - (3,4-diethylbenzyl) -2- [4- (1-methyl-piperidin-4-yl) -piperazine-1-yl] -2-oxo-ethyl} -amide-dimaleinate (6a).

FIG. 22 shows the X-ray powder diffractogram of the crystalline compound 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid {(/?) - 1 - (3,4-diethylbenzyl) -2- [4- (1-methyl-piperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl} -amide-p-toluenesulfonate (6b).

FIG. 23 shows the X-ray powder diffractogram of the crystalline compound 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid {(/?) - 1 - (3,4-diethylbenzyl) -2- [4- (1-methyl-piperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl} -amide-benzenesulfonate (6c).

FIG. 24 shows the X-ray powder diffractogram of the crystalline compound 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid {(/?) - 1 - (3,4-diethylbenzyl) -2- [4- (1-methyl-piperidin-4-yl) -piperazine-1-yl] -2-oxo-ethyl} -amide-naphthalene-1,5-disulfonate (6d).

FIG. 25 shows the X-ray powder diffractogram of the crystalline compound 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid {(/?) - 1 - (3,4-diethylbenzyl) -2- [4- (1-methyl-piperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl} -amide-naphthalene-2-sulfonate (6e ).

Claims

1. Crystalline compounds A of the general formula I. in the A ¹ Br, -CF ₃ , -CH ₃ or -C ₂ H ₅ , A ^{2 is} -NH ₂ , -OH or -C ₂ H ₅ , A ³ Br, Cl, -CH ₃ or H, X is -CH ₂ -, -NH- or -O-, Y ¹ N or CH, Y ² N or CH and Y ^{3 is} -CH ₂ -, -N (CH ₃ ) - or -O-, and which are present in the form of their physiologically tolerated salts with acids, the acids being selected from the group B consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, benzenesulphonic acid, p-toluenesulphonic acid, maleic acid, succinic acid, fumaric acid, D - (-) Tartaric acid, L - (+) - tartaric acid, Naphthalene-2-sulfonic acid and naphthalene-1, 5-disulfonic acid, as well as the polymorphs, the corresponding solvates and hydrates. 2. Crystalline compounds A of the general formula I according to claim 1, which are selected from the group consisting of and in the form of their physiologically acceptable salts with acids B selected from hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, benzenesulfonic acid, p-toluenesulfonic acid, maleic acid, succinic acid, fumaric acid, D - (-) - tartaric acid, L - (+ ) -Wine acid, naphthalene-2-sulfonic acid and naphthalene-1, 5-disulfonic acid, as well as the polymorphs, the corresponding solvates and hydrates. 3. The following crystalline compounds of general formula I according to claim 1: (1a) 1 - [4-Amino-3,5-dibromo-Λ / - [[4- (2,3,4,5-tetrahydro-2 (1 H) -oxo-1,3-benzodiazepine] yl) -1-piperidinyl] carbonyl] -D-phenylalanyl] -4- (1-piperidinyl) piperidine p-toluene sulfonate, (1 b) 1 - [4-Amino-3,5-dibromo-Λ / - [[4- (2,3,4,5-tetrahydro-2 (1 H) -oxo-1,3-benzodiazepine] 3 -yl) -1-piperidinyl] carbonyl] -D-phenylalanyl] -4- (1-piperidinyl) -piperidine-benzenesulfonate, (1 c) 1 - [4-Amino-3,5-dibromo-Λ / - [[4- (2,3,4,5-tetrahydro-2 (1 H) -oxo-1,3-benzodiazepine] 3 -yl) -1-piperidinyl] carbonyl] -D-phenylalanyl] -4- (1-piperidinyl) -piperidine-maleate, (2a) 4- (2-oxo-1, 2,4,5-tetrahydro-1, 3-benzodiazepin-3-yl) -piperidine-1 -carboxylic acid (R) -1 ^■ (4-amino-3- chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methyl-1-piperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl dimaleinate, (2b) 4- (2-oxo-1, 2,4,5-tetrahydro-1, 3-benzodiazepin-3-yl) -piperidine-carboxylic acid 1 - (/?) - 1 ^■ (4-amino-3 -chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester hydrobromide, (2c) 4- (2-oxo-1, 2,4,5-tetrahydro-1, 3-benzodiazepin-3-yl) -piperidine-1 -carboxylic acid (R) -1 ^■ (4-amino-3- chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidirid-1-yl] -2-oxo-ethyl ester dihydrobromide, (2d) 4- (2-oxo-1, 2,4,5-tetrahydro-1, 3-benzodiazepin-3-yl) -piperidine-1 -carboxylic acid (R) -1 ^■ (4-amino-3- chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidirid-1-yl] -2-oxo-ethyl ester hydrochloride, (2e) 4- (2-oxo-1, 2,4,5-tetrahydro-1, 3-benzodiazepin-3-yl) -piperidine-1 -carboxylic acid (R) -1 ^■ (4-amino-3- chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidirid-1-yl] -2-oxo-ethyl ester difumarate, (2f) 4- (2-oxo-1, 2,4,5-tetrahydro-1, 3-benzodiazepin-3-yl) -piperidine-1 -carboxylic acid (R) -1 ^■ (4-amino-3- chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methyl-piperazin-1-yl) -piperidiri- 1-yl] -2-oxo-ethyl ester disuccinate, (2g) 4- (2-Oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid- (R) -1 ^■ (4-Amino-3-chloro-5-trifluoromethylbenzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester sulfate, (3a) 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / - 1, 3-benzdiazepin-3-yl) - (1R) - 1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester hydrobromide (3b) 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / - 1, 3-benzdiazepin-3-yl) - (1R) -1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester hydrochloride, (3c) 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / - 1, 3-benzdiazepin-3-yl) - (1R) -1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester phosphate, (3d) 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / - 1, 3-benzdiazepin-3-yl) - (1R) - 1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester (2R, 3R) -2, 3-dihydroxybutanedioate, (3e) 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / - 1, 3-benzdiazepin-3-yl) - (1R) - 1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester (2S, 3S) -2, 3-dihydroxybutanedioate, (4a) 4- (2-Oxo-1, 2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - (I?) - 1 - (4-hydroxy-3 , 5-dimethyl-benzyl) -2-oxo-2- [4- (tetrahydropyran-4-yl) -piperazin-1-yl] -ethyl ester fumarate, (4b) 4- (2-Oxo-1,2,4,5,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - (?) -1- (4-hydroxy-3 , 5-dimethyl-benzyl) -2-oxo-2- [4- (tetrahydropyran-4-yl) -piperazin-1-yl] -ethyl ester sulfate, (5a) (S) -2- (4-Amino-3-chloro-5-trifluoromethyl-benzyl) -1 - [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -4 [4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidin-1-yl] -butane-1,4-dione hydrochloride pentahydrate, (5b) (S) -2- (4-Amino-3-chloro-5-trifluoromethyl-benzyl) -1 - [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -4 - [4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidin-1-yl] -butane (2S, 3S) -2,3-dihydroxybutanedioate . (5c) (S) -2- (4-Amino-3-chloro-5-trifluoromethyl-benzyl) -1 - [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -4 [4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidin-1-yl] -butane-1,4-dione hydrobromide pentahydrate, (6a) 4- (2-Oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid {(/?) - 1 - (3,4-) diethyl-benzyl) -2- [4- (1-methylpiperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl} -amide Dimaleinat, (6b) 4- (2-Oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid {(/?) - 1 - (3,4-) diethyl-benzyl) -2- [4- (1-methyl-piperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl} -amide-p-toluenesulfonate, (6c) 4- (2-Oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - {(/?) - 1 - (3,4-) diethyl-benzyl) -2- [4- (1-methyl-piperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl} -amide-benzenesulfonate, (6d) 4- (2-Oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - {(/?) - 1 - (3,4-) diethyl-benzyl) -2- [4- (1-methylpiperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl} -amide Naphthalene-1, 5-disulfonate and (6e) 4- (2-Oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - {(/?) - 1 - (3,4-) diethyl-benzyl) -2- [4- (1-methylpiperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl} -amide-naphthalene-2-sulfonate, their polymorphs, their solvates and their hydrates. 4. The crystalline compound (1a) according to claim 3, characterized by a melting point of T _Smp = 180 ± 5 ° C. 5. The crystalline compound (1 b) according to claim 3, characterized by a melting point of T _Smp = 183 ± 5 ° C. 6. The crystalline compound (1c) according to claim 3, characterized by a melting point of Tsmp = 191 ± 5 ° C. 7. The crystalline compound (2a) according to claim 3, characterized by a melting point of T _Smp = 200 ± 5 ° C. 8. The crystalline compound (2b) according to claim 3, characterized by a melting point of T _Smp = 238 ± 5 ° C. 9. The crystalline compound (2c) according to claim 3, characterized by a melting point of T _Smp = 277 ± 5 ° C. 10. The crystalline compound (2e) according to claim 3, characterized by a melting point of T _Smp = 218 ± 5 ° C. 1 1. The crystalline compound (2f) according to claim 3, characterized by a melting point of T _Smp = 133 ± 5 ° C. 12. The crystalline compound (2g) according to claim 3, characterized by a melting point of T _Smp = 165 ± 5 ° C. 13. The crystalline compound (3a) according to claim 3, polymorph 1), characterized by a melting point of T _Sm p = 186 ± 5 ° C. 14. The crystalline compound (3a) according to claim 3, polymorph 2), characterized by a melting point of T _Sm p = 170 ± 5 ° C. 15. The crystalline compound (3b) according to claim 3, polymorph 1), characterized by a melting point of T _Smp = 176 ± 5 ° C. 16. The crystalline compound (3b) according to claim 2, polymorph 2), characterized by a melting point of T _Smp = 174 ± 5 ° C. 17. The crystalline compound (3c) according to claim 3, characterized by a melting point of T _Smp = 209 ± 5 ° C. 18. The crystalline compound (3d) according to claim 3, characterized by a melting point of T _Smp = 195 ± 5 ° C. 19. The crystalline compound (3e) according to claim 3, characterized by a melting point of T _Smp = 175 ± 5 ° C. 20. The crystalline compound (4a) according to claim 3, characterized by a melting point of T _Smp = 222 ± 5 ° C. 21. The crystalline compound (4b) according to claim 3, characterized by a melting point of T _Smp = 143 ± 5 ° C. 22. The crystalline compound (5a) according to claim 3, characterized by a melting point of T _Smp = 136 ± 5 ° C. 23. The crystalline compound (5b) according to claim 3, characterized by a melting point of T _Smp = 144 ± 5 ° C. 24. The crystalline compound (6a) according to claim 3, characterized by a melting point of T _Smp = 165 ± 5 ° C. 25. The crystalline compound (6b) according to claim 3, characterized by a melting point of T _Smp = 142 ± 5 ° C. 26. The crystalline compound (6c) according to claim 3, characterized by a melting point of T _Smp = 199 ± 5 ° C. 27. The crystalline compound (6d) according to claim 3, characterized by a melting point of T _Smp = 204 ± 5 ° C. 28. The crystalline compound (6e) according to claim 3, characterized by a melting point of T _Smp = 172 ± 5 ° C. 29. Crystalline 1 - [4-amino-3,5-dibromo-Λ / - [[4- (2,3,4,5-tetrahydro-2 (1 H) -oxo-1,3-benzodiazepine] 3-yl) -1-piperidinyl] carbonyl] -D-phenylalanyl] -4- (1-piperidinyl) piperidine p-toluenesulfonate (1a), characterized in that, in the X-ray powder diagram, it has the characteristic values d = 19.49 Ä, 12.16 Ä, 6.46 Ä, 6.08 Ä, 5.4 Ä, 5.17 Ä and 3.82 Ä. 30. Crystalline 1 - [4-amino-3,5-dibromo-Λ / - [[4- (2,3,4,5-tetrahydro-2 (1 H) -oxo-1,3-benzodiazepine] 3-yl) -1-piperidinyl] carbonyl] -D-phenylalanyl] -4- (1-piperidinyl) -piperidine-benzenesulfonate (1 b), characterized in that, in the X-ray powder diagram, it has the characteristic values d = 17.6 Ä, 12.29 Ä, 7.24 Ä, 5.84 Ä and 5.34 Ä. 31. Crystalline 1- [4-amino-3,5-dibromo-Λ / - [[4- (2,3,4,5-tetrahydro-2 (1 / - /) -oxo-1,3-benzo] diazepin-3-yl) -1-piperidinyl] carbonyl] -D-phenylalanyl] -4- (1-piperidinyl) piperidine maleate (1c), characterized in that, in the X-ray powder diagram, it has the characteristic values d = 16.14 Ä , 11.7 Ä, 6.3 Ä, 5.04 Ä, 4.61 Ä, 4.43 Ä, 4.03 Ä and 3.8 Ä. 32. Crystalline 4- (2-oxo-1, 2,4,5-tetrahydro-1,3-benzdiazepin-3-yl) -piperidine-1-carboxylic acid (R) -1- (4-amino) 3-chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl-ester-dimaleinate (2a), characterized in that in the X-ray powder diagram it has among others the characteristic values d = 7.92 Å, 5.45 Å, 5.29 Å, 4.99 Å, 4.66 Å and 4.45 Å. 33. Crystalline 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - (/?) - 1- (4-amino 3-chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester hydrobromide (2b), characterized characterized in that it has in the X-ray powder diagram, among others, the characteristic values d = 4.71 Ä, 4.49 Ä, 4.39 Ä, 3.77 Ä, 3.71 Ä and 3.45 Å. 34. Crystalline 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - (I?) - 1- (4-amino 3-chloro-5-trifluoromethylbenzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester dihydrobromide (2c), characterized characterized in that it has in the X-ray powder diagram among others the characteristic values d = 21.69 Å, 5.81 Å, 4.74 Å, 4.63 Å, 4.15 Å and 3.78 Å. 35. Crystalline 4- (2-oxo-1, 2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - (/?) - 1- (4-amino 3-chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester hydrochloride (2d), characterized characterized in that it is in X-ray powder diagram among others the characteristic values d = 7.59 Ä, 5.78 Ä, 4.95 Ä, 4.69 Ä, 4.59 Ä, 4.12 Ä and 3.73 Ä. 36. Crystalline 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - (/?) - 1- (4-amino 3-chloro-5-trifluoromethyl-benzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester difumarate (2e), characterized characterized in that it has in the X-ray powder diagram, among others, the characteristic values d = 8.16 Ä, 6.29 Ä, 5.21 Ä, 4.63 Ä, 4.37 Ä and 3.72 Ä. 37. Crystalline 4- (2-oxo-1, 2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - (/?) - 1- (4-amino 3-chloro-5-trifluoromethylbenzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester disuccinate (2f), characterized characterized in that it has in the X-ray powder diagram, among others, the characteristic values d = 8.18 Ä, 6.46 Ä, 5.26 Ä, 5.18 Ä, 4.61 Ä and 4.32 Å. 38. Crystalline 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - (/?) - 1- (4-amino -3-chloro-5-trifluoromethylbenzyl) -2- [4- (4-methylpiperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester sulfate (2g), by characterized in that it has in the X-ray powder diagram, among others, the characteristic values d = 5.98 Ä, 5.78 Ä, 5.37 Ä, 4.24 Ä and 4.02 Å. 39. Crystalline 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / - 1, 3-benzdiazepin-3-yl) - (1R) -1 - [ (4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester hydrobromide (3a, polymorph 1), characterized in that it is known in the X-ray powder diagram among others the characteristic values d = 7.86 Ä, 6.18 Ä, 5.81 Ä, 4.66 Ä and 4.06 Ä. 40. Crystalline 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / - 1, 3-benzdiazepin-3-yl) - (1R) -1 - [ (4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester hydrobromide (3a, polymorph 2), characterized in that it is known in the X-ray powder diagram among others the characteristic values d = 25.99 Ä, 7.73 Ä, 7.10 Ä, 6.05 Ä, 5.89 Ä, 4.28 Ä and 3.92 Ä. 41. Crystalline 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / - 1, 3-benzdiazepin-3-yl) - (1R) -1 - [ (4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester hydrochloride (3b, polymorph 1), characterized in that it is known in the X-ray powder diagram among others the characteristic values d = 7.68 Ä, 6.15 Ä, 5.79 Ä, 4.64 Ä, 4.15 Ä and 4.03 Ä. 42. Crystalline 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / - 1, 3-benzdiazepin-3-yl) - (1R) -1 - [ (4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester hydrochloride (3b, polymorph 2), characterized in that it is known in the X-ray powder diagram, among others, the characteristic values d = 7.74 Ä, 7.13 Ä, 6.00 Ä, 5.88 Ä and 4.22 Ä. 43. Crystalline 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / - 1, 3-benzodiazepin-3-yl) - (1R) -1 - [ (4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester phosphate (3c), characterized in that it is in the X-ray powder diagram, among others the characteristic values d = 8.90 Ä, 5.53 Ä, 5.15 Ä, 4.83 Ä and 4.63 Ä. 44. Crystalline 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / - 1, 3-benzdiazepin-3-yl) - (1R) -1 - [ (4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester (2R, 3R) -2,3-dihydroxybutanedioate (3d) , characterized in that it has in the X-ray powder diagram, among others, the characteristic values d = 10.02 Ä, 8.90 Ä, 5.54 Ä, 5.20 Ä, 4.88 Ä and 4.67 Å. 45. Crystalline 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / - 1, 3-benzdiazepin-3-yl) - (1R) -1 - [ (4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester (2S, 3S) -2,3-dihydroxybutanedioate (3e) , characterized in that it has in the X-ray powder diagram, among others, the characteristic values d = 8.97 Ä, 5.57 Ä, 5.17 Ä, 4.87 Ä and 4.65 Ä. 46. Crystalline 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid (R) -1- (4-hydroxy) 3,5-dimethylbenzyl) -2-oxo-2- [4- (tetrahydropyran-4-yl) -piperazin-1-yl] -ethyl ester fumarate (4a), characterized in that it is present in the X-ray powder diacid among others has the characteristic values d = 9.01Ä, 6.30Ä, 5.26 Ä, 5.07 Ä, 4.72 Ä and 4.52 Ä. 47. Crystalline 4- (2-oxo-1, 2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - (/?) - 1- (4-hydroxy -3,5-dimethylbenzyl) -2-oxo-2- [4- (tetrahydropyran-4-yl) piperazin-1-yl] ethyl ester sulfate (4b), characterized in that it is in the X-ray powder diagram, among others the characteristic values d = 12.79 Ä, 10.80 Ä, 5.23 Ä, 4.65 Ä and 4.18 Ä. 48. Crystalline (S) -2- (4-amino-3-chloro-5-trifluoromethyl-benzyl) -1- [4- (4-methyl-piperazin-1-yl) -piperidin-1-yl] -4- [4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidin-1-yl] -butane-1,4-dione hydrochloride pentahydrate (5a), characterized in that it has in the X-ray powder diagram, among others, the characteristic values d = 7.29 Ä, 7.2 Ä, 5.84 Ä, 4.42 Ä and 4.1 1 Ä. 49. Crystalline (S) -2- (4-amino-3-chloro-5-trifluoromethylbenzyl) -1 - [4- (4-methyl-piperazin-1-yl) -piperidin-1-yl] -4- [4- (2-oxo-1, 2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidin-1-yl] -butane (2S, 3S) -2,3 Dihydroxybutandioat (5b), characterized in that it has in the X-ray powder diagram, among others, the characteristic values d = 10.21 Ä, 5.67 Ä, 4.7 Ä, 4.51 Ä and 4.14 Ä. 50. Crystalline (S) -2- (4-amino-3-chloro-5-trifluoromethyl-benzyl) -1 - [4- (4-methyl-piperazin-1-yl) -piperidin-1-yl] -4- [4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidin-1-yl] -butane-1,4-dione hydrobromide pentahydrate (5c), characterized in that it has in the X-ray powder diagram, among others, the characteristic values d = 7.22 Å, 5.83 Å, 4.65 Å, 4.52 Å, 4.12 Å and 3.75 Å. 51. Crystalline 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - {(R) -1- (3,4 -diethyl-benzyl) -2- [4- (1-methyl-piperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl} -amide-dimaleinate (6a), characterized in that it is in the X-ray powder diagram among others has the characteristic values d = 21.21 Ä, 9.99 Ä, 5.52 Ä, 5.33 Ä, 4.81 Ä and 3.99 Ä. 52. Crystalline 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - {(/?) - 1- (3, 4-diethyl-benzyl) -2- [4- (1-methyl-piperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl} -amide-p-toluenesulfonate (6b), characterized that in the X-ray powder diagram it has among others the characteristic values d = 25.57 Å, 8.59 Å, 7.61 Å, 7.04 Å, 6.19 Å and 5.25 Å. 53. Crystalline 4- (2-oxo-1, 2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - {(R) -1- (3,4 -diethyl-benzyl) -2- [4- (1-methyl-piperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl} -amide-benzenesulfonate (6c), characterized in that it is known in the X-ray powder diagram among others the characteristic values d = 10.53 Ä, 6.68 Ä, 5.87 Ä, 5.10 Ä and 5.00 Ä. 54. Crystalline 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - {(R) -1- (3,4 -diethyl-benzyl) -2- [4- (1-methylpiperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl} -amide-naphthalene-1, 5-disulfonate (6d), characterized in that it has in the X-ray powder diagram, among others, the characteristic values d = 8.47 Å, 7.15 Å, 6.95 Å, 5.29 Å, 4.41 Å, 4.07 Å and 3.47 Å. 55. Crystalline 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzadiazepin-3-yl) -piperidine-1-carboxylic acid - {(/?) - 1 - (3, 4-diethyl-benzyl) -2- [4- (1-methyl-piperidin-4-yl) -piperazine-1-yl] -2-oxo-ethyl} -amide-naphthalene-2-sulfonate (6e), characterized characterized in that it has in the X-ray powder diagram, among others, the characteristic values d = 9.93 Ä, 8.75 Ä, 8.22 Ä, 7.43 Ä, 6.21 Ä, 4.42 Ä and 4.23 Å. 56. A pharmaceutical composition containing a compound according to any one of claims 1 to 55 besides optionally one or more inert carriers and / or diluents. 57. Use of the compound according to any one of claims 1 to 55 for the manufacture of a medicament for the acute and prophylactic treatment of headache, in particular migraine and cluster headache and tension headache, for the treatment of non-insulin-dependent diabetes mellitus ("NIDDM"), cardiovascular diseases , Morphine tolerance, Clostridiumtoxin- caused diarrheal diseases, diseases of the skin, especially thermal and Radiation-induced skin damage including sunburn, sunburn, prurigo, pruriginous toxidermias and severe itching, inflammatory diseases, eg inflammatory joint diseases (osteoarthritis, rheumatoid arthritis, neurogenic arthritis), generalized soft-tissue rheumatism (fibromyalgia), neurogenic inflammations of the oral mucosa, inflammatory lung diseases, allergic rhinitis, asthma , COPD, for the treatment of diseases associated with excessive vasodilation and consequent reduced tissue perfusion, eg, shock and sepsis, chronic pain disorders such as diabetic neuropathies, chemotherapy-induced neuropathies, HIV-induced neuropathies, postherpetic neuropathies, tissue trauma-induced neuropathies , trigeminal neuralgia, temporomandibular dysfunctions, CRPS (complex regional pain syndrome), back pain and for the treatment of visceral diseases, preferably irritable bowel syndrome (IBS) and inflammatory bowel syndrome, or for the preventive and acute-therapeutic treatment of the symptoms of menopausal, caused by vasodilation and increased blood flow hot flashes of estrogen-deficient women and hormone-treated prostate cancer patients and castrates. 58. Use of a compound according to any one of claims 1 to 55 for the manufacture of a medicament for the acute and prophylactic treatment of migraine and cluster headache. 59. Use of a compound according to any one of claims 1 to 55 for the manufacture of a medicament for the treatment of irritable bowel syndrome (IBS). 60. Use of a compound according to any one of claims 1 to 55 for Production of a drug for the preventive and acute therapeutic treatment of hot flashes of women with estrogen deficiency. 61. A process for the preparation of a medicament according to claim 56, characterized in that a compound according to one of the non-chemical way Claims 1 to 55 incorporated in one or more inert carriers and / or diluents. 62. Process for Preparing the Crystalline Salt 1-Piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / 1, 3-benzdiazepin-3-yl) - (1R) - 1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester (2R, 3 /?) - 2,3 dihydroxybutanedioate (3d), comprising the following steps: (a) Mixing the base 1-piperidinecarboxylic acid 4- (1,2,4,5-tetrahydro-2-oxo-3 / - / -1,3-benzodiazepin-3-yl) - (1 /?) - 1 - [(4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester with a first solvent at room temperature and then heating the resulting suspension; (b) adding a second solvent and then heating the reaction mixture; (c) dropwise adding a concentrated solution of (L) - (+) - tartaric acid in water; (d) slowly cooling the reaction mixture, filtering off and drying the crystals formed. 63. The method according to claim 62, characterized in that as solvent in step (a) methanol, ethanol, propanol, isopropanol or a mixture of these solvents is used. 64. The method according to claim 62, characterized in that as solvent in step (a) ethanol or isopropanol or a 1: 1 mixture of ethanol and Isopropanol is used. 65. The method according to claim 62, characterized in that the solvent in step (a) is used in an amount of 2 to 5 ml / mmol of base used. 66. The method according to claim 62, characterized in that the solvent in step (a) is used in an amount of 3 to 4 mL / mmol of base used. 67. The method according to claim 62, characterized in that the suspension formed in step (a) is then heated to a temperature of 50 to 60 ° C. 68. The method according to claim 62, characterized in that as solvent in step (b) methanol, ethanol, propanol, isopropanol or a mixture of these Solvents is used. 69. The method according to claim 62, characterized in that as solvent in step (b) ethanol or isopropanol or a 1: 1 mixture of ethanol and isopropanol is used. 70. The method according to claim 62, characterized in that the solvent in step (b) is used in an amount of 2 to 5 in L / mmol of base used. 71. The method according to claim 62, characterized in that the solvent in step (b) is used in an amount of 3 to 4 mL / mmol of base used. 72. The method according to claim 62, characterized in that the reaction mixture obtained in step (b) is then heated to a temperature of 70 to 80 ° C. 73. The method according to claim 62, characterized in that the reaction mixture obtained in step (b) is then heated to a temperature of 74 to 76 ° C. 74. The method according to claim 62, characterized in that as solvent in step (a) ethanol and as solvent in step (b) isopropanol is used. 75. The method according to claim 62, characterized in that in step (c) one of the amount of tartaric acid used equivalent amount of water is used. 76. The method according to claim 62, characterized in that in step (c) the water is used in an amount of 0.9 to 1.1 g / g of tartaric acid used. 77. The method according to claim 62, characterized in that in step (c) the water is used in an amount of 1.0 g / g of tartaric acid used. 78. Crystalline 1-piperidinecarboxylic acid 4- (1, 2,4,5-tetrahydro-2-oxo-3 / - / - 1, 3-benzdiazepin-3-yl) - (1R) -1 - [ (4-hydroxy-3,5-dimethylphenyl) methyl] -2- [4- (4-morpholinyl) -1-piperidinyl] -2-oxoethyl ester (2R, 3R) -2,3-dihydroxybutanedioate, prepared according to A method according to any one of claims 62 to 77.